A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Vina P NguyenKatie M CampbellTheodore Scott NowickiNila ElumalaiEgmidio MedinaIgnacio Baselga CarreteroMaggie L DiNomeHelena R ChangDenise K OsegueraAntoni RibasJohn A GlaspyPublished in: Cancer research communications (2023)
Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity.